secwatch.observer — SEC 8-K summary
======================================

Issuer:     Atara Biotherapeutics, Inc. (ATRA)
CIK:        0001604464
Form:       8-K
Filed at:   2024-01-08T23:59:59+00:00
Accession:  0001193125-24-003945
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.05, 5.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Atara cuts 25% of workforce, restructures to focus on CAR-T; CMO departs
------------------------------------------------------------------------

- Workforce reduction of ~25% (approx. 56 employees) expected to complete by May 2024; severance costs ~$4.5M.
- CMO Manher Joshi to depart Feb 2, 2024; receives 12 months severance, $3k/month consulting fee, $185k tab-cel BLA milestone.
- Restructuring plus $27M upfront from Pierre Fabre pact and existing cash expected to fund operations into 2027.
- Tab-cel BLA on track for Q2 2024 submission; pivotal ALLELE study showed ORR 49% (p<0.0001).
- IND for ATA3219 in Lupus Nephritis planned Q1 2024; preliminary clinical data in lymphoma expected H2 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1604464/000119312524003945/0001193125-24-003945-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1604464/000119312524003945/d703405d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-003945

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer